SCHEMBL679200

SCHEMBL679200

Nc1ccc(NC(=O)c2ccc3ccccc3c2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DEGS1 O15121 1/20 0.74
NPC1 O15118 7/20 0.68
RAB9A P51151 7/20 0.68
CASP3 P42574 1/20 0.68
SENP7 Q9BQF6 1/20 0.68
KDM4E B2RXH2 1/20 0.68
MEN1 O00255 6/20 0.67
KMT2A Q03164 6/20 0.67
POLB P06746 2/20 0.66
TDP1 Q9NUW8 2/20 0.66
LMNA P02545 1/20 0.66
PKM P14618 1/20 0.66
APEX1 P27695 1/20 0.66
NR1H4 Q96RI1 1/20 0.65
PLAU P00749 4/20 0.65
MAPT P10636 1/20 0.62
MCL1 Q07820 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
F2 P00734 2/20 0.61
PLG P00747 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22695574 0.93 POLB (0.75) DEGS1NPC1RAB9ACASP3SENP7
SCHEMBL8420152 0.90 NPC1 (0.72) DEGS1NPC1RAB9ACASP3SENP7
SCHEMBL7491147 0.88 NR1H4 (0.88) DEGS1NPC1RAB9ACASP3SENP7
SCHEMBL28013893 0.87 PLAU (0.74) DEGS1MEN1KMT2APOLBTDP1
SCHEMBL21446854 0.87 PLAU (0.79) DEGS1NPC1RAB9ACASP3SENP7
SCHEMBL26885220 0.87 DEGS1 (0.79) DEGS1NPC1RAB9ACASP3SENP7
SCHEMBL2467402 0.86 PLAU (0.78) DEGS1NPC1RAB9ACASP3SENP7
SCHEMBL7491143 0.86 NR1H4 (0.67) DEGS1NPC1RAB9ACASP3SENP7
SCHEMBL7890716 0.85 DEGS1 (1.00) DEGS1NPC1RAB9ACASP3SENP7
SCHEMBL3656661 0.85 DEGS1 (0.77) DEGS1NPC1RAB9ACASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-11-03 US claimed
JP-2011526912-A 2011-10-20 JP claimed
EP-2291376-A2 NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS Merck Patent GmbH (DE) 2011-03-09 EP claimed
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-11-03 US disclosed
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-11-03 US disclosed
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-11-03 US disclosed
EP-2291376-A2 NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS Merck Patent GmbH (DE) 2011-03-09 EP disclosed
WO-2010002779-A2 NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS MERCK SERONO S.A. (CH) 2010-01-07 WO disclosed
US-6380243-B1 INCLUDING HUMAN CYTOMEGALOVIRUS, HERPES SIMPLEX VIRUSES, EPSTEIN-BARR VIRUS, VARICELLA-ZOSTER VIRUS, HUMAN HERPESVIRUSES- 6 AND -7, AND KAPOSI HERPESVIRUS. AMERICAN HOME PRODUCTS CORPORATION 2002-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS AURKA, AURKC, AURKB DEGS1 3689/4885NPC1 1978/4885RAB9A 2275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.